AzTrials
AzTrials

Transcranial Magnetic StimulationNCT05625386

Dual-target, High-dose TMS for PD Patients With FOG

A study testing transcranial magnetic stimulation in people with Transcranial Magnetic Stimulation and Freezing of Gait, run by Anhui Medical University at 1 site in China.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The aim of the current study was to verify whether high-dose TMS treatment of the motor and cognitive cortices is more effective in alleviating FOG than conventional-dose TMS of the motor cortex only. Read more about this study

Who is it for?
Ages 40 to 85 years
What is being tested?
transcranial magnetic stimulation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
64 participants
Where
1 siteChina
Study dates
22 Dec 2022to 31 Mar 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • diagnosis of FOG with expertise in movement disorders.
  • the score of item 3 of the FOG questionnaire ≥1.
  • ongoing treatment with a stable dose of any medication for 2 months.
  • 40 years of age or older.

Who cannot join

  • a history of addiction, psychiatric disorders, or neurological diseases other than PD.
  • focal brain lesions on T1-/T2-weighted fluid-attenuated inversion recovery images.
  • anti-PD medication adjustments during rTMS treatment.
  • history of substance abuse within the past 6 months.
  • nonremovable metal objects in or around the head.
  • previously received rTMS treatment.
  • prior history of seizure or history in first-degree relatives.

Trial locations and contacts

1 site in 1 country.

China1 site
  • Cognitive Neuropsychology Lab Anhui Medical University

    Hefei, Anhui, 230032

Other trials in China

About this study

Official title: Dual-target, High-dose, Transcranial Magnetic Stimulation for Parkinson's Disease With Freezing of Gait

The aim of the current study was to verify whether high-dose TMS treatment of the motor and cognitive cortices is more effective in alleviating FOG than conventional-dose TMS of the motor cortex only. Specifically, investigator hypothesized that the effect of dual-target TMS on FOG is better than traditional stimulation of the motor cortex only, and the effect of high-dose TMS is better than conventional doses.

Read the detailed description

This was an open-label, randomized controlled study. Participants were randomized in a 1:1:1 fashion to receive dual-target, high-dose TMS (DHT), dual-target, conventional-dose TMS (DCT), and single-target, conventional-dose TMS (SCT). SCT was designated as the control group with protocol reference to evidence-based guidelines, while DHT and DCT served as the experimental groups.

DHT refers to the left primary motor cortex of the lower leg (M1) and dorsolateral prefrontal cortex (DLPFC) receiving 9000 pulses/day of intermittent TBS (iTBS) for 5 consecutive days. DCT refers to the left M1 and DLPFC receiving 1800 pulses/day of iTBS for 5 consecutive days. The order of stimulation for the two targets was randomized across participants and the order of stimulation within participants remained unchanged throughout the session. SCT refers to the left M1 receiving 1800 pulses/day of iTBS treatment for 5 consecutive days.

Motor and cognitive measures were performed ("on medication" state) 1 day before TMS (baseline), 1 day after completion of TMS (post), and 1 month after completion of TMS (follow-up). The primary outcome of this study was the change in FOGQ scores from baseline to follow-up. Secondary outcomes included changes in the Unified Parkinson's Disease Rating Scale Part III (UPDRS III), 5 m Timed Up-and-Go test (TUG), FOG-provoking test (Standing-Start 180° Turn Test, SS-180), Stroop color-naming (SCN), Stroop word-reading (SWR), Stroop color-word (SCW), and Color Trails Test interference index (CTTII) from baseline to follow-up.

Evaluate the patient's brain function and structural changes by collecting Rest-EEG,transcranial magnetic stimulation-EEG, near-infrared functional brain imaging (fNIRS)and fMRI.

TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by the participant's anatomical image (1 × 1 × 1 mm3) and a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).

Stimulation intensity: Because each participant had different sensitivity to TMS, the individual Resting Motor Threshold (RMT) was measured before intervention. Specifically, surface electrodes (Ag/AgCl) were attached to both ends of the right abductor pollicis muscle (the ground wire was connected to the ulnar styloid process) and the left finger motor cortex was stimulated one time. The motor-evoked potentials were recorded from the hand muscles. The RMT was considered when the evoked potential > 50 μV occurred in > 5 of 10 consecutive stimulations. The stimulation intensity during intervention was 80% of the RMT in the current study.

Stimulation sequence: Each iTBS sequence in the high-dose stimulation sequence released 900 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of 10 iTBS sessions was performed each day with an interval of 40 min and the daily stimulation dose was 9000 pulses. Each iTBS sequence in the conventional-dose stimulation sequence released 600 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of three iTBS sessions were performed each day with an interval of 40 min and the daily stimulation dose was 1800 pulses.

Stimulation targets: There were two stimulation targets in this study that were used to intervene in the motor and cognitive cortices. The stimulation target of the motor cortex is located in the lower leg of the left primary motor cortex in the Montreal Neurological Institute space (coordinates: -10, -24, 75 [https:/ /afni.nimh.nih.gov/MNI_Atlas]) based on structural MRI. The stimulation target of the cognitive cortex was the left dorsolateral prefrontal cortex, which has the strongest functional connectivity with the executive control network (see Supplementary materials), based on fMRI. Finally, targets were transformed into the native space for each participant by applying an inverse matrix produced during brain structure and function segmentation using SPM12 (www.fil.ion.ucl.ac.uk/spm) and TMStarget software.

Keywords
Transcranial Magnetic Stimulation, Freezing of Gait

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • transcranial magnetic stimulationDevice

    TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).

Study groups in NCT05625386
Study groupRoleWhat they receive
Dual-target high-dose TMS (DHT)ExperimentalDHT refers to the left primary motor cortex of the lower leg (M1) and dorsolateral prefrontal cortex (DLPFC) receiving 9000 pulses/day of intermittent TBS (iTBS) for 5 consecutive days. Each iTBS sequence in the high-dose stimulation sequence released 900 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of 10 iTBS sessions was performed each day with an interval of 40 min and the daily stimulation dose was 9000 pulses. The order of stimulation for the two targets was randomized across participants and the order of stimulation within participants remained unchanged throughout the session.
Receives: Device: transcranial magnetic stimulation
Dual-target conventional-dose TMS (DCT)ExperimentalDCT refers to the left M1 and DLPFC receiving 1800 pulses/day of iTBS for 5 consecutive days. Each iTBS sequence in the conventional-dose stimulation sequence released 600 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of three iTBS sessions were performed each day with an interval of 40 min and the daily stimulation dose was 1800 pulses.The order of stimulation for the two targets was randomized across participants and the order of stimulation within participants remained unchanged throughout the session.
Receives: Device: transcranial magnetic stimulation
Single-target conventional-dose TMS (SCT)Active comparatorSCT refers to the left M1 receiving 1800 pulses/day of iTBS treatment for 5 consecutive days. Each iTBS sequence in the conventional-dose stimulation sequence released 600 pulses at a time with a pulse cluster repeated every 200 ms at a frequency of 5 Hz. Each pulse cluster contained three pulses with a frequency of 50 Hz, stimulation time of 2 s, and interval of 8 s. A total of three iTBS sessions were performed each day with an interval of 40 min and the daily stimulation dose was 1800 pulses.
Receives: Device: transcranial magnetic stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The Freezing of Gait Questionnaire (FOGQ) scores

    This is an very common clinical motor estimating scale for evaluating FOG. 6 items and each item scored between 0 and 4 points (24 scores in total). Higher scores mean a worse outcome

    Measured: the changes in FOGQ scores from baseline to 1 month after completion of TMS (follow-up).

Secondary outcomes (5)
  1. The timed up and go test (TUG)

    The participants walk for a distance of five meters from a sitting position and come back to the chair after turning 180° around a traffic cone in a 0.7 m × 0.7 m target box .The time during the whole course are measured. The time is recorded in seconds, and the longer the time, the more severe the symptoms.The longer it takes, the worse it gets

    Measured: changes from baseline to 1 month after completion of TMS (follow-up).

  2. Unified Parkinson's Disease Rating Scale III (UPDRSIII) scores

    This is an very common clinical motor estimating scale, 14 items and 108' in total. Higher scores indicate worse symptoms. Higher scores mean a worse outcome.

    Measured: changes from baseline to 1 month after completion of TMS (follow-up).

  3. Stroop test

    stroop color word test is generally divided into three parts: (1) Quick naming of color dot plots (SCN); (2) Recite the nouns representing the color names quickly (SWR); (3) Present a set of cards, in which the nouns representing the color names are written on the cards in different colors, and check the ability of the subjects to distinguish between the color names and the actual colors, as well as the ability to recite the nouns representing the color names quickly (SCW). The degree to which subjects were influenced by font color as an indicator (SCW) of their cognitive control. The longer it takes, the worse it gets.

    Measured: changes (SCN, SWR, SCW) from baseline to 1 month after completion of TMS (follow-up).

  4. Color Trails Test interference index (CTTII)

    The number color connection test was divided into two parts, A and B. Part A asked the subjects to connect 25 numbers on the paper in order. In Part B, numbers and letters were replaced by numbers of two different colors to eliminate the influence of culture on the test. When the subjects were asked to connect numbers in order, the two graphs were arranged alternately. The measurement index was time, and the longer the time, the more obvious the decline in prompt ability. CTTII=CTT(part B)-CTT(part A). The longer it takes, the worse it gets.

    Measured: changes rom baseline to 1 month after completion of TMS (follow-up).

  5. The Standing-Start 180° Turn Test (SS-180)

    The participants walk for a distance of five meters from a sitting position and come back to the chair after turning 180° around a traffic cone in a 0.7 m × 0.7 m target box.The time during the 180° turn (SS180) are measured. The time is recorded in seconds, and the longer the time, the more severe the symptoms. The longer it takes, the worse it gets.

    Measured: changes from baseline to 1 month after completion of TMS (follow-up).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2022
  2. Study start22 Dec 2022
  3. Primary completion25 Feb 2024
  4. Study completion31 Mar 2024

Why it stopped: The study was halted at the midpoint because the interim analysis demonstrated a large effect size of the DHT group compared with the SCT group (Cohen's d = 1.58).

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
64 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05625386
Sponsor's protocol ID
AHMU-TMS-FOG-twotargets
Status last verified
Apr 2024
First submitted
29 Jun 2022
Last updated
19 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing transcranial magnetic stimulation in people with Transcranial Magnetic Stimulation and Freezing of Gait, run by Anhui Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 19 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: The study was halted at the midpoint because the interim analysis demonstrated a large effect size of the DHT group compared with the SCT group (Cohen's d = 1.58).). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The Freezing of Gait Questionnaire (FOGQ) scores (time frame: the changes in FOGQ scores from baseline to 1 month after completion of TMS (follow-up).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in